ANTH Share Price

Open 2.50 Change Price %
High 2.59 1 Day 0.01 0.39
Low 2.13 1 Week -0.37 -12.63
Close 2.56 1 Month -0.52 -16.88
Volume 1371004 1 Year -3.38 -56.90
52 Week High 6.46
52 Week Low 2.13
ANTH Important Levels
Resistance 2 2.99
Resistance 1 2.81
Pivot 2.43
Support 1 2.31
Support 2 2.13
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
EBAY 29.02 -10.76%
EBAY 29.02 -10.76%
GTAT 0.44 0.00%
MSFT 57.25 -0.49%
MSFT 57.25 -0.49%
NASDAQ USA Top Gainers Stocks
DSTI 0.12 300.00%
DRWI 4.29 94.12%
ULTR 0.13 85.71%
LOCM 0.09 50.00%
SCHS 0.12 33.33%
MNKD 0.61 29.79%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
PGRX 0.04 -42.86%

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH)

ANTH Technical Analysis 5
As on 20th Oct 2016 ANTH Share Price closed @ 2.56 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.55 & Strong Sell for SHORT-TERM with Stoploss of 3.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
ANTH Target for October
1st Target up-side 3.42
2nd Target up-side 3.61
3rd Target up-side 3.8
1st Target down-side 2.88
2nd Target down-side 2.69
3rd Target down-side 2.5
ANTH Other Details
Segment EQ
Market Capital 65433428.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website
ANTH Address
25801 Industrial Boulevard
Suite B
Hayward, CA 94545
United States
Phone: 510-856-5600
Fax: 510-856-5597
Interactive Technical Analysis Chart Anthera Pharmaceuticals, Inc. ( ANTH NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Anthera Pharmaceuticals, Inc.
ANTH Business Profile
Anthera Pharmaceuticals, Inc. (Anthera), incorporated on September 9, 2004, is a development-stage, biopharmaceutical company focused on developing and commercializing products to treat diseases associated with inflammation. As of December 31, 2011, the Company had one Phase-II clinical program, blisibimod. Two of its product candidates, varespladib and varespladib sodium, are designed to inhibit an enzyme target known as secretory phospholipase A2 (sPLA2). sPLA2 have been implicated in a range of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome associated with sickle cell disease, as well as in chronic diseases, including stable coronary artery disease (CAD). In addition, blisibimod targets B-lymphocyte stimulator (BLyS), also known as B-cell Activating Factor (BAFF), which has been associated with a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, lupus nephritis (LN), vasculitis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. It has rights to develop and commercialize its products in all indications and markets, with the exception of Japan where Shionogi & Co., Ltd. retains commercial rights to its sPLA2 product candidates. The Company’s sPLA2 inhibitors has been studied in a range of inflammatory disorders in multiple therapeutic areas. Its sPLA2 inhibitors on sPLA2 concentration and activity have been implicated in acute coronary syndrome and acute chest syndrome associated with sickle cell disease. It has the two sPLA2 inhibitors in clinical development. Its first product candidate, varespladib (an oral prodrug of varespladib sodium), is a spectrum inhibitor of sPLA2 enzymes, including type IIa, V and X. Varespladib, when combined with Lipitor (atorvastatin), is a therapeutics in development to offer a treatment approach targeting systemic inflammation, elevated lipid levels and the inflammatory path of atherosclerosis. Through its mechanism of action, varespladib may have applications in a range of acute and chronic cardiovascular diseases.